Humanigen, EVERSANA to partner for launch, commercialisation of Lenzilumab for COVID-19 treatment

Humanigen and EVERSANA announced that they are partnering to make lenzilumab available to hospitalised and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the US Food and Drug Administration (FDA) and subsequent BLA.

Humanigen’s investigational treatment, lenzilumab, a proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is designed to prevent and treat cytokine storm, a complication considered to be a leading cause of COVID-19 death.

Under the terms of the agreement, and in anticipation of a EUA for the use of lenzilumab in hospitalised COVID-19 patients, Humanigen has immediate access to EVERSANA’s services including, but not limited to, marketing, market access, medical education, health economics and outcomes research, medical information, compliance and medical science liaison teams, with each service optimised by data and predictive analytics. The agreement with EVERSANA builds on the commercial preparation and lenzilumab launch planning Humanigen has been conducting over the last several months.

*Source: National Institute of Allergy and Infectious Diseases’ Adaptive COVID-19 Treatment Trial (ACT-1)